Caldan Therapeutics develops novel therapeutics targeting free fatty acid receptors to address metabolic diseases such as Type 2 Diabetes and non-alcoholic steatohepatitis (NASH). The company leverages expertise in GPCR drug discovery to create effective treatments that improve metabolic health outcomes.
Funding
$18.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LFounders
Product
Problem
Metabolic diseases like Type 2 Diabetes and non-alcoholic steatohepatitis (NASH) require effective therapeutic interventions to improve patient outcomes. Current treatments may not fully address the underlying mechanisms of these diseases, leaving a need for novel therapeutic approaches.
Solution
Caldan Therapeutics develops innovative therapeutics targeting free fatty acid receptors (FFARs) to combat metabolic diseases. By focusing on FFARs, which play a crucial role in metabolic regulation, the company aims to create treatments that directly address the root causes of diseases like Type 2 Diabetes and NASH. Caldan Therapeutics leverages its expertise in G protein-coupled receptor (GPCR) drug discovery to design and develop effective therapies that can improve metabolic health. The company's approach seeks to provide targeted and efficacious treatments for patients suffering from these debilitating conditions.
Target Audience
The primary target audience includes individuals suffering from metabolic diseases such as Type 2 Diabetes and non-alcoholic steatohepatitis (NASH).
Features
- Focus on activators of free fatty acid receptors (FFARs) implicated in Type 2 Diabetes.
- Expertise in G protein-coupled receptor (GPCR) drug discovery.
- Development of novel therapeutics for metabolic diseases.
- Targeting of non-alcoholic steatohepatitis (NASH) and inflammatory diseases.